Učitavanje...
A Novel RXR Agonist, UAB30, Inhibits Rhabdomyosarcoma Cells in Vitro
BACKGROUND: While patients with early stage rhabdomyosarcoma (RMS) have seen steady improvement in prognosis over the last fifty years, those with advanced stage or high grade disease continue to have a dismal prognosis. Retinoids have been shown to cause growth suppression and terminal differentiat...
Spremljeno u:
| Izdano u: | J Surg Res |
|---|---|
| Glavni autori: | , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6007849/ https://ncbi.nlm.nih.gov/pubmed/29907230 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jss.2018.02.057 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|